Vericel Reports Record Third Quarter Revenues, Net Income and Operating Cash Flow
Click here to read the press release

Vericel manufactures advanced cell therapies for the sports medicine and severe burn care markets. The goal of our therapies is to repair or restore a patient’s damaged tissues or organs using their own cells. Please use the links to the right to visit our product websites.

NASDAQ: VCEL

$18.54 -0.27 (0%)
Day High: $18.85
Day Low: $18.38
Volume: 659031
4:00 PM on
November 14, 2019
Copyright West LLC. Minimum 15 minutes delayed.

Company Presentation